Retrophin starts Phase III of RE-024 to treat PKAN

Retrophin Inc. (NASDAQ:RTRX) began the international Phase III FORT trial of fosmetpantotenate (RE-024) to treat pantothenate kinase-associated neurodegeneration (PKAN). The double-blind, placebo-controlled trial will evaluate the primary endpoint of change from baseline to week 24 in PKAN Activities of Daily Living (PKAN-ADL) scale score in about 82 patients. The secondary endpoint is change from baseline to week 24 in Unified Parkinson’s Disease Rating Scale (UPDRS) score...